查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1492596

巨細胞病毒治療市場：按疾病、藥物、分銷管道、應用分類 - 全球預測 2024-2030

Cytomegalovirus Treatment Market by Diseases (Encephalitis, Gastrointestinal Ulcers, Pneumonia), Drug (Cidofovir, Foscarnet, Ganciclovir), Distribution Channel, Application - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

巨細胞病毒治療市場規模預計2023年為5.3844億美元，2024年達到5.7699億美元，預計2030年將達到9.0339億美元，複合年成長率為7.67%。

巨細胞病毒(CMV) 治療包括管理和治療巨細胞病毒感染的整體醫療程序。巨細胞病毒是一種常見病毒，屬於皰疹組，常見於免疫力缺乏的患者和孕婦。治療包括抗病毒藥物和疫苗，如西多福韋、膦甲酸、更昔洛韋和纈更昔洛韋，主要用於醫院和診所。巨細胞病毒盛行率的不斷增加以及對有效治療和預防措施的需求正在推動對各種巨細胞病毒（CMV）治療的需求。此外，隨著愛滋病毒/愛滋病、癌症治療和器官移植等疾病導致免疫力缺乏的患者數量不斷增加，對強大的 CMV 管理解決方案的需求也迅速增加。然而，對鉅細胞病毒株的抗藥性以及與先進治療相關的高成本是低收入地區鉅細胞病毒治療面臨的挑戰。與先進治療相關的高成本和 CMV 挖掘阻力問題阻礙了市場成長。此外，對 CMV 普遍缺乏認知阻礙了 CMV 相關疾病的早期診斷和開始治療。監管環境也是一個挑戰，嚴格的醫藥品認證過程可能會減緩新治療方法的推出。然而，由於改善藥物傳遞的奈米技術、個人化醫療的基因研究以及匯集資源和專業知識以增強治療解決方案的合作研究等創新，該市場具有廣闊的成長潛力。

主要市場統計
基準年[2023] 53844萬美元
預測年份 [2024] 57699萬美元
預測年份 [2030] 90339萬美元
複合年成長率（%） 7.67%

區域洞察

在美國，先進的研究、全面的健康保險和活躍的新療法市場正在推動 CMV 治療。加拿大政府資助的醫療保健系統確保持續獲得​​ CMV 治療，這是市場成長的動力。在南美洲，提高意識和有針對性的教育計劃，特別是有關先天性鉅細胞病毒的教育計劃，正在支持市場成長，從而改善早期診斷並擴大治療覆蓋範圍。在亞太地區，中國的醫療改革促進了獲得治療的機會，日本透過完善的醫療保險體系提供了廣泛的涵蓋範圍，而印度儘管基礎設施存在差距，但改善了獲得治療的機會，特別是在都市區進展迅速。同時，東南亞國家正在透過推動研究和採用新的臨床設施和 CMV 療法來增加其全球臨床影響力。在歐洲、中東和非洲，歐盟國家正在大力投資鉅細胞病毒治療的研究和進展。在中東國家，特別是阿拉伯聯合大公國和沙烏地阿拉伯，隨著大眾對鉅細胞病毒治療的認知不斷提高，醫療設施迅速發展，治療可能性不斷擴大。在非洲，新的 CMV 治療方法正在透過國際援助和發展計劃得到採用，重點是改善整體健康狀況，以支持市場成長。

FPNV定位矩陣

FPNV 定位矩陣對於評估供應商在巨細胞病毒治療市場的定位至關重要。此矩陣提供了對供應商的全面評估，並檢查了與商務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果，供應商被分為代表其成功程度的四個像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對巨細胞病毒治療市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻，您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他關鍵指標。此外，該分析還提供了對該行業競爭力的寶貴見解，包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊，供應商可以做出更明智的決策並製定有效的策略，以在市場競爭中保持領先地位。

策略分析與建議

策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對巨細胞病毒治療市場當前地位的全面評估使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析，以確定核心優勢和需要改進的領域。

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 巨細胞病毒感染的傳播
      • 提高對 CMV 及其影響的認知以及不斷上漲的醫療費用
    • 抑制因素
      • 治療成本高且商業化受到限制
    • 機會
      • CMV診療技術進展
      • 增加對醫療基礎設施的投資，以改善獲得先進 CMV 治療的機會
    • 任務
      • CMV 治療開發中的監管和標準化挑戰
  • 市場區隔分析
    • 藥物：更昔洛韋的使用增加，這是治療巨細胞病毒的主要藥物
    • 分銷管道：透過提供個人化指導和頻繁給藥，擴大醫院藥房獲得 CMV 治療的機會
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章巨細胞病毒治療市場：依疾病分類

  • 腦炎
  • 胃腸道潰瘍
  • 肺炎
  • 視網膜炎

第7章巨細胞病毒治療市場：依藥物分類

  • 西多福韋
  • 膦甲酸
  • 更昔洛韋
  • 纈更昔洛韋

第8章巨細胞病毒治療市場：按分銷管道

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第9章巨細胞病毒治療市場：依應用分類

  • 先天性鉅細胞病毒感染疾病
  • 器官移植
  • 幹細胞移植

第10章美洲巨細胞病毒治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區巨細胞病毒治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的巨細胞病毒治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 移植後巨細胞病毒感染新療法「Livtencity」在中國核准
    • 默克公司的 PREVYMIS 獲得 CHMP核准，用於在腎臟和幹細胞移植患者中擴大 CMV 預防
    • 美國市售的 Kamata CYTOGAM 功能增強和肺移植中 CMV 預防的顯著臨床資料
  • 戰略分析和建議

第14章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-7949F05839D1

[196 Pages Report] The Cytomegalovirus Treatment Market size was estimated at USD 538.44 million in 2023 and expected to reach USD 576.99 million in 2024, at a CAGR 7.67% to reach USD 903.39 million by 2030.

The cytomegalovirus (CMV) treatment includes all aspects of medical practices to manage and treat cytomegalovirus infections, a common virus in the herpes group, found predominantly in immunocompromised individuals and pregnant women. The treatment includes antiviral drugs and vaccines such as cidofovir, foscarnet, ganciclovir & valganciclovir, which hospitals & clinics predominately utilize. The increased prevalence of cytomegalovirus and the acute need for its effective treatment and preventive measures drive the need for various cytomegalovirus (CMV) treatments. Moreover, with the rising number of immunocompromised patients owing to conditions such as HIV/AIDS, cancer therapies, and organ transplants, there is a burgeoning need for robust CMV management solutions. However, dug-resistant to CMV strains and the high cost associated with advanced treatment are the challenges faced by CMV treatments in low-income regions. High costs associated with advanced treatment and dug-resistant issues with CMV hamper the market growth. Additionally, a general lack of awareness about CMV hinders early diagnosis and treatment initiation for CMV-related diseases. The regulatory landscape also presents challenges, with stringent drug approval processes potentially slowing the introduction of new therapies. However, the market holds promising potential for growth through innovations such as nanotechnology for improved drug delivery, genetic research for personalized medicine, and collaborative efforts that pool resources and expertise for enhanced treatment solutions.

KEY MARKET STATISTICS
Base Year [2023] USD 538.44 million
Estimated Year [2024] USD 576.99 million
Forecast Year [2030] USD 903.39 million
CAGR (%) 7.67%

Regional Insights

In the Americas, the United States is involved in advanced research, comprehensive health insurance, and a proactive market for new treatments, which drive CMV treatment. Canada's government-funded healthcare system ensures consistent access to CMV therapies, which drives market growth. In South America, raising awareness and targeted educational programs, particularly concerning congenital CMV, are improving early diagnosis and expanding treatment coverage to support market growth. In the Asia Pacific region, China's healthcare reforms have boosted treatment access, Japan offers extensive coverage through a refined health insurance system, and India, despite its infrastructural discrepancies, is quickly advancing in treatment availability, particularly in urban centers. Meanwhile, Southeast Asian countries are enhancing their global clinical presence by advancing research and adopting new clinical facilities and medication for CMV treatments. In Europe, the Middle East, and Africa, the EU countries have invested considerably in research and the advancement of CMV treatment. In the Middle East, countries, particularly the UAE and Saudi Arabia, are rapidly developing medical facilities and expanding treatment availability, paralleled by growing public awareness related to CMV treatments. In Africa, the adoption of newer CMV treatments through international aid and developmental programs focusing on improving overall health outcomes supports market growth.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Cytomegalovirus Treatment Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Increasing prevalence of cytomegalovirus infections
      • Increasing awareness about CMV and its implications, coupled with rising healthcare spending
    • Market Restraints
      • High cost of treatment coupled with limited commercialization
    • Market Opportunities
      • Advancements in CMV diagnosis and treatment technologies
      • Growing investment in healthcare infrastructure to increase the accessibility of advanced CMV treatments
    • Market Challenges
      • Regulatory and standardization challenges in CMV treatment development
  • Market Segmentation Analysis
    • Drug: Growing usage of ganciclovir primary medication to treat cytomegalovirus
    • Distribution Channel: Growing accessibility of CMV treatments across Hospital pharmacies as it provides personal guidance and frequent medication
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cytomegalovirus Treatment Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cytomegalovirus Treatment Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Approval of LIVTENCITY in China a Novel Treatment for Post-Transplant Cytomegalovirus Infections

Takeda Pharmaceutical announced that China's National Medical Products Administration has granted approval for LIVTENCITY (maribavir) to treat adult patients who have had either hematopoietic stem cell or solid organ transplants and are facing cytomegalovirus (CMV) infections that have shown resistance to conventional treatments. The approval was influenced by the Phase 3 SOLSTICE trial results, illustrating that LIVTENCITY is more effective than traditional antiviral therapies in achieving CMV viremia clearance eight weeks post-treatment. This marks the twelfth global approval of LIVTENCITY, reinforcing its therapeutic significance and international acceptance in handling challenging post-transplant CMV cases. [Published On: 2023-12-21]

Merck's PREVYMIS Gains CHMP Endorsement for Extended CMV Prophylaxis in Kidney and Stem Cell Transplant Recipients

Merck has received a favorable opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). This recommendation endorses the use of PREVYMIS (letermovir) to prevent cytomegalovirus (CMV) disease in high-risk adult transplant recipient groups. PREVYMIS has demonstrated effectiveness in clinical trials, specifically in a Phase 3 trial with 589 adult kidney transplant recipients and a placebo-controlled study focused on extended dosing for HSCT patients. [Published On: 2023-10-17]

Kamada's CYTOGAM Enhancements in U.S. Commercial Availability and Notable Clinical Data on CMV Prophylaxis in Lung Transplants

Kamada Ltd. has achieved USFDA approval for CYTOGAM to prevent cytomegalovirus (CMV) disease among various organ transplant recipients. Following a successful FDA-approved transfer of its manufacturing process to Kamada's facility in Beit Kama, Israel, the product is now available for U.S. commercial sale, with expectations to reach the Canadian market by year-end. Additionally, groundbreaking clinical data was unveiled at IDWeek 2023 in Boston, showcasing a five-year retrospective study by Dr. Fernando Torres at the University of Texas Southwestern Medical Center. [Published On: 2023-10-16]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cytomegalovirus Treatment Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Cytomegalovirus Treatment Market, highlighting leading vendors and their innovative profiles. These include Aetos Pharma Private Limited, Ajanta Pharma Ltd., Cipla Limited, Emcure Pharmaceuticals Limited, Exela Pharma Sciences, LLC, F. Hoffmann-La Roche Ltd, Fresenius Kabi AG, GlaxoSmithKline PLC, LEXICARE PHARMA PVT. LTD., Merck & Co., Inc, Rakshit Pharmaceuticals Limited, Teva Pharmaceutical Industries Ltd., Weefsel Pharma, and Xediton Pharmaceuticals Inc..

Market Segmentation & Coverage

This research report categorizes the Cytomegalovirus Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Diseases
    • Encephalitis
    • Gastrointestinal Ulcers
    • Pneumonia
    • Retinitis
  • Drug
    • Cidofovir
    • Foscarnet
    • Ganciclovir
    • Valganciclovir
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Application
    • Congenital CMV Infection
    • Organ Transplantation
    • Stem Cell Transplantation
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cytomegalovirus infections
      • 5.1.1.2. Increasing awareness about CMV and its implications, coupled with rising healthcare spending
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment coupled with limited commercialization
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in CMV diagnosis and treatment technologies
      • 5.1.3.2. Growing investment in healthcare infrastructure to increase the accessibility of advanced CMV treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory and standardization challenges in CMV treatment development
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug: Growing usage of ganciclovir primary medication to treat cytomegalovirus
    • 5.2.2. Distribution Channel: Growing accessibility of CMV treatments across Hospital pharmacies as it provides personal guidance and frequent medication
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Cytomegalovirus Treatment Market, by Diseases

  • 6.1. Introduction
  • 6.2. Encephalitis
  • 6.3. Gastrointestinal Ulcers
  • 6.4. Pneumonia
  • 6.5. Retinitis

7. Cytomegalovirus Treatment Market, by Drug

  • 7.1. Introduction
  • 7.2. Cidofovir
  • 7.3. Foscarnet
  • 7.4. Ganciclovir
  • 7.5. Valganciclovir

8. Cytomegalovirus Treatment Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Online Pharmacy
  • 8.4. Retail Pharmacy

9. Cytomegalovirus Treatment Market, by Application

  • 9.1. Introduction
  • 9.2. Congenital CMV Infection
  • 9.3. Organ Transplantation
  • 9.4. Stem Cell Transplantation

10. Americas Cytomegalovirus Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cytomegalovirus Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cytomegalovirus Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Approval of LIVTENCITY in China a Novel Treatment for Post-Transplant Cytomegalovirus Infections
    • 13.3.2. Merck's PREVYMIS Gains CHMP Endorsement for Extended CMV Prophylaxis in Kidney and Stem Cell Transplant Recipients
    • 13.3.3. Kamada's CYTOGAM Enhancements in U.S. Commercial Availability and Notable Clinical Data on CMV Prophylaxis in Lung Transplants
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CYTOMEGALOVIRUS TREATMENT MARKET DYNAMICS
  • FIGURE 7. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. CYTOMEGALOVIRUS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. CYTOMEGALOVIRUS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CYTOMEGALOVIRUS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ENCEPHALITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ENCEPHALITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY GASTROINTESTINAL ULCERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY GASTROINTESTINAL ULCERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PNEUMONIA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY PNEUMONIA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY RETINITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY RETINITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY CIDOFOVIR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY CIDOFOVIR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY FOSCARNET, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY FOSCARNET, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY GANCICLOVIR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY GANCICLOVIR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY VALGANCICLOVIR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY VALGANCICLOVIR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY CONGENITAL CMV INFECTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY CONGENITAL CMV INFECTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ORGAN TRANSPLANTATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY ORGAN TRANSPLANTATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 53. ARGENTINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 54. ARGENTINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 55. ARGENTINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 56. ARGENTINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 57. ARGENTINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 58. ARGENTINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 59. ARGENTINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 60. ARGENTINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 61. BRAZIL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 62. BRAZIL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 63. BRAZIL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 64. BRAZIL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 65. BRAZIL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 66. BRAZIL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 67. BRAZIL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 68. BRAZIL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 69. CANADA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 70. CANADA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 71. CANADA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 72. CANADA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 73. CANADA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 74. CANADA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 75. CANADA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 76. CANADA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 77. MEXICO CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 78. MEXICO CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 79. MEXICO CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 80. MEXICO CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 81. MEXICO CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 82. MEXICO CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 83. MEXICO CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 84. MEXICO CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 85. UNITED STATES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 86. UNITED STATES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 87. UNITED STATES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 88. UNITED STATES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 89. UNITED STATES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 90. UNITED STATES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 91. UNITED STATES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 92. UNITED STATES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 93. UNITED STATES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 94. UNITED STATES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 106. AUSTRALIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 108. AUSTRALIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 110. AUSTRALIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 112. AUSTRALIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 113. CHINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 114. CHINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 115. CHINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 116. CHINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 117. CHINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 118. CHINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 119. CHINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 120. CHINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 121. INDIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 122. INDIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 123. INDIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 124. INDIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 125. INDIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 126. INDIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 127. INDIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 128. INDIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 129. INDONESIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 130. INDONESIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 131. INDONESIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 132. INDONESIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 133. INDONESIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 134. INDONESIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 135. INDONESIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 136. INDONESIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 137. JAPAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 138. JAPAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 139. JAPAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 140. JAPAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 141. JAPAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 142. JAPAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 143. JAPAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 144. JAPAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 145. MALAYSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 146. MALAYSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 147. MALAYSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 148. MALAYSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 149. MALAYSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 150. MALAYSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 151. MALAYSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 152. MALAYSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 154. PHILIPPINES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 156. PHILIPPINES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 157. PHILIPPINES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 158. PHILIPPINES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 160. PHILIPPINES CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 161. SINGAPORE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 162. SINGAPORE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 163. SINGAPORE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 164. SINGAPORE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 165. SINGAPORE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 166. SINGAPORE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 167. SINGAPORE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 168. SINGAPORE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 170. SOUTH KOREA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 172. SOUTH KOREA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 173. SOUTH KOREA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 174. SOUTH KOREA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 175. SOUTH KOREA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 176. SOUTH KOREA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 177. TAIWAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 178. TAIWAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 179. TAIWAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 180. TAIWAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 181. TAIWAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 182. TAIWAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 183. TAIWAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 184. TAIWAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 185. THAILAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 186. THAILAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 187. THAILAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 188. THAILAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 189. THAILAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 190. THAILAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 191. THAILAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 192. THAILAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 193. VIETNAM CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 194. VIETNAM CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 195. VIETNAM CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 196. VIETNAM CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 197. VIETNAM CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 198. VIETNAM CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 199. VIETNAM CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 200. VIETNAM CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 211. DENMARK CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 212. DENMARK CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 213. DENMARK CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 214. DENMARK CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 215. DENMARK CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 216. DENMARK CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 217. DENMARK CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 218. DENMARK CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 219. EGYPT CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 220. EGYPT CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 221. EGYPT CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 222. EGYPT CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 223. EGYPT CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 224. EGYPT CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 225. EGYPT CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 226. EGYPT CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 227. FINLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 228. FINLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 229. FINLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 230. FINLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 231. FINLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 232. FINLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 233. FINLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 234. FINLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 235. FRANCE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 236. FRANCE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 237. FRANCE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 238. FRANCE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 239. FRANCE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 240. FRANCE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 241. FRANCE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 242. FRANCE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 243. GERMANY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 244. GERMANY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 245. GERMANY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 246. GERMANY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 247. GERMANY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 248. GERMANY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 249. GERMANY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 250. GERMANY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 251. ISRAEL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 252. ISRAEL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 253. ISRAEL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 254. ISRAEL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 255. ISRAEL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 256. ISRAEL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 257. ISRAEL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 258. ISRAEL CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 259. ITALY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 260. ITALY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 261. ITALY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 262. ITALY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 263. ITALY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 264. ITALY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 265. ITALY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 266. ITALY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 268. NETHERLANDS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 270. NETHERLANDS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 271. NETHERLANDS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 272. NETHERLANDS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 273. NETHERLANDS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 274. NETHERLANDS CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 275. NIGERIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 276. NIGERIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 277. NIGERIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 278. NIGERIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 279. NIGERIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 280. NIGERIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 281. NIGERIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 282. NIGERIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 283. NORWAY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 284. NORWAY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 285. NORWAY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 286. NORWAY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 287. NORWAY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 288. NORWAY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 289. NORWAY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 290. NORWAY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 291. POLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 292. POLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 293. POLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 294. POLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 295. POLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 296. POLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 297. POLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 298. POLAND CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 299. QATAR CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 300. QATAR CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 301. QATAR CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 302. QATAR CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 303. QATAR CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 304. QATAR CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 305. QATAR CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 306. QATAR CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 307. RUSSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 308. RUSSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 309. RUSSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 310. RUSSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 311. RUSSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 312. RUSSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 313. RUSSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 314. RUSSIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 316. SAUDI ARABIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 317. SAUDI ARABIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 318. SAUDI ARABIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 319. SAUDI ARABIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 320. SAUDI ARABIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 321. SAUDI ARABIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 322. SAUDI ARABIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2018-2023 (USD MILLION)
  • TABLE 324. SOUTH AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISEASES, 2024-2030 (USD MILLION)
  • TABLE 325. SOUTH AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 326. SOUTH AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 327. SOUTH AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 328. SOUTH AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 329. SOUTH AFRICA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 330. SOUTH AFRICA CYTOMEGALOVIRUS TREATMENT MAR